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A well-characterized protein kinase C (PKC) activity, associated with the secretion and aggregation functions, has been previously described in human platelets. T h e phenothiazine, chlorpromazinc, is an amphiphilic cationic drug which interferes with the organization o f biological membranes and is known as a non-specific inhibitor (at SO0 p~) of 47 kDa protein (P47) phosphorylation and aggrcgation induced by thrombin in washed platelets (iti vivo), as well as a good PKC activity inhibitor in partially purified or crude extracts (iti vitro) [ I I. T h e tumour promoter, phorbol cstcr (TPA), activates platelet PKC, as monitored by activity determination or by phosphorylation o f the P47, and a TPAdependent dense-granule secretion in platelets, independent of C a 2 + mobilization has also bccn shown [ 1, 21. However, increasing concentrations o f chlorpromazine (30-500 p~) caused a progressive lysis of gel-filtered platelets; the lysis was markedly enhanced by thrombin and TPA at 100 p~-chlorpromazine. At non-lytic concentration (below 30 p~) , the drug caused an increase in the thrombin-o r TPAmediated phosphorylation of phosphoinositides and had n o effect on the P47 phosphorylation, but inhibited the ATP+ A D P secretion [3, 4] .
In view of these results, we decided to invcstigatc the ability of chlorpromazine t o interfere with the PKC translocation and/or activation in intact platelets stimulated with TPA. T h e cells, 1.5-2 x IO''/ml, were prepared by the method of Baenziger & Majerus 1.51; the PKC translocation was determined as previously described [2] . In the presence of leupcptin and other proteinase inhibitors, PKC activity was measured in soluble (S) and particulate ( P ) fractions using [ y3'P]ATP (3000 Ci/mmol) as described [ 61. T h e number of cells in each translocation assay was S x 10x/ml.
Protein concentrations in the assay of S and P fractions were routinely 200 pg/ml and I 0 0 pg/ml, respectively.
Previously, we determined (Fig. l a ) the effect of TPA o r chlorpromazine on the PKC activity in platelet crude extract (in vilro). T h e dose-rcsponsc curve for PKC activation by In experimentation iri vivo, intact platclcts were preincubated for 1 0 min with 30 o r 100 pM-chlorpromazine. After this time 0.1 ~M -T P A was added t o thc assay mixture and the PKC activity was determined in the S and P fractions at different times after TPA exposure. T h e results are shown in Fig. I(h) . After 1 0 min o f 100 pM-drUg exposure, the values of both S and P fraction activities were the same as that shown in control platelets incubated without drug, s o the chlorpromazine by itself did not affect the translocation o f PKC activity from thc S t o the P fraction. T h e basal lcvels of cytosolic Ca' + -dependent kinases were almost constant ovcr all the assay time. TPA-induced translocation started immcdiately and reached a maximum 1 min after TPA addition. Chlorpromazine preincubation ( 100 p~) was unable to block the TPA-induccd translocation; in spite of this, it has been reported that 100 phkchlorpromazine inhibits the P47 phosphorylation, and dense granule and ATP secretion [ 3, 41. At non-lytic (30 p~) drug concentration, the profile shown by chlorpromazinc ( 1 0 min preincubation before 0.1 ~M -T P A addition) was the same as that found at 100 ~U M (Fig. I h ) (data not shown); in this casc, P47 phosphorylation takes place 131, but inhibition o f ATP secretion was described 141.
Only 2S'X lysis has been reported whcn platelets were preincubated for 2 min with 100 pM-chIorpromazinc and then further incubated for 2 min with 0.17 ~M -T P A 131. These authors suggested that the previously reported inhibition of the P47 phosphorylation by the drug [ 1 ] was due t o thc cytolysis carried out by thc drug at high concentration, SO0 p~, when thrombin was present. Non-lytic conccntrations of the drug inhibited secretion, but slightly inhibited the phosphorylation of P47 in the presence of 0.1 7 ~M -T P A 131 ( i t . in 1 min, no changes were detected, but in 2 min they found a 35% of inhibition on the P47 phosphorylation).
We have demonstrated here that 0.1 ~M -T P A induces the complete translocation in 1 min, s o the drug did not inhibit or interferc with the PKC translocation by TPA, but inhibits, Then 0.1 ~M -T P A was added to the incubation mixture; the reaction was stopped at different times and the cells were collected by centrifugation at low temperature. S and P fractions were obtained as described 121. PKC activity was measured over 4 min in the presence of 2.4 x l o -' M-free calcium and 4 0 pg of PS/ml in both the S (.) and the P ( 0 ) fraction; the enzyme activity of the soluble fraction in the presence of calcium alone is also shown ( 0 ) . PKC activity of control cells, incubated with 0.1 ~M -T P A for 1 min without preincubating with chlorpromazine, was also measured in the presence of both calcium and PS in the S ( A ) and P ( A ) fraction. the protein interacts with the plasma membrane (at S O 0 ,LAMchlorpromazine, P47 phosphorylation and secretion were abolished). These results did not exclude the possibility that the P47 phosphorylation could be a necessary step in the stimulus-secretion coupling. Moreover, they demonstrate that 30 pM-drug inhibits a step after PKC activation.
T h c TPA-induced PKC translocation to the plasma membranes can occur without requiring full or partial activation o f the enzyme. T h e protein could be translocated by TPA o r DAG and would modulate its activity in the plasma membrane. T h e related chlorpromazine-induced inhibition on TPA-stimulated secretion, at lytic and non-lytic drug conccntration. may be due t o a blockage of the plasma membrane phospholipid turnover, resulting in a gradual decrease o f membrane fluidity. In this way. it has been reported [7] that 100 pM-chhrpromazine causes 50% of phosphatidylethanolamine methyltransferase inhibition in plasma membranes. Such an enzyme has been associated with membrane repair mechanisms, as well as with structural changes, which may render cell membranes more sensitive t o activation.
